T1	PrimaryOutcome 59 87	time to clinical improvement
T2	OutcomeDefinition 100 147	the days from randomization until normalization
T3	OutcomeDefinition 212 338	body temperature, respiratory rate, oxygen saturation, alleviation of cough, and absorption of pulmonary infection by chest CT
R1	DefinedAs Arg1:T1 Arg2:T2	
R2	DefinedAs Arg1:T1 Arg2:T3	
T4	SecondaryOutcome 1021 1046	clinical improvement rate
T5	SecondaryOutcome 1048 1091	median time and proportion of defervescence
T6	SecondaryOutcome 1093 1172	mean time and proportion of significant inflammatory absorption of lung lesions
T7	SecondaryOutcome 1176 1231	negative conversion rate of the viral nucleic acid test
T8	SecondaryOutcome 1233 1242	mortality
T9	TimeFrame 1243 1252	at day 28
R3	MeasuredAt Arg1:T8 Arg2:T9	
T10	SecondaryOutcome 1262 1330	conversion from mild or ordinary to severe or critical severe status
T11	OutcomeDefinition 1543 1636	days from randomization to a temperature less than 37.0 Â°C maintained for at least 24 or 72 h
R4	DefinedAs Arg1:T5 Arg2:T11	
T12	TimeFrame 1680 1732	repeated after 48 h following a negative test result
R5	MeasuredAt Arg1:T7 Arg2:T12	
T14	OtherOutcome 2026 2189	changes in laboratory indicators, including routine blood test, C-reactive protein (CRP), coagulation function, myocardial enzymes, and hepatic and renal functions
T13	OutcomeDefinition 1448 1492	according to Chinese guidelines for COVID-19
R6	DefinedAs Arg1:T10 Arg2:T13	
T15	OutcomeDefinition 1834 1932	patient being discharged from the hospital or the score decreasing by two points from the baseline
R7	DefinedAs Arg1:T4 Arg2:T15	
T16	OutcomeDefinition 1738 1828	conversion rate in severe and critical severe subjects was assessed with a six-point scale
R8	DefinedAs Arg1:T10 Arg2:T16	
T17	OtherOutcome 2195 2257	recovery rates of the above indicators from abnormal to normal
